New real-world data shows minimed™ 780g system sustains strong global performance, exceeding international targets for diabetes management

New data presented at attd demonstrates the system's ability to help individuals with type 1 diabetes exceed international targets on outcome measures dublin and florence, italy , march 9, 2024 /prnewswire/ -- medtronic plc. (nyse: mdt), a global leader in healthcare technology, today shared a robust set of new clinical and real-world evidence on the minimed™ 780g system from around the world including the largest set of data from early users in the united states.
MDT Ratings Summary
MDT Quant Ranking